	US 12,173,372 B2
	Liver cancer detection kit or device, and detection method
Satoshi Kondou, Kamakura (JP); Hitoshi Nobumasa, Kamakura (JP); Satoko Kozono, Kamakura (JP); Hiroko Sudo, Kamakura (JP); Junpei Kawauchi, Kamakura (JP); Atsushi Ochiai, Kashiwa (JP); and Motohiro Kojima, Kashiwa (JP)
Assigned to TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed on Oct. 20, 2023, as Appl. No. 18/491,272.
Application 18/491,272 is a division of application No. 17/970,824, filed on Oct. 21, 2022, granted, now 11,827,941.
Application 17/970,824 is a division of application No. 16/785,233, filed on Feb. 7, 2020, granted, now 11,512,355, issued on Nov. 29, 2022.
Application 16/785,233 is a division of application No. 15/319,585, granted, now 10,590,487, issued on Mar. 17, 2020, previously published as PCT/JP2015/067552, filed on Jun. 18, 2015.
Claims priority of application No. 2014-124880 (JP), filed on Jun. 18, 2014.
Prior Publication US 2024/0052429 A1, Feb. 15, 2024
Int. Cl. C12Q 1/68 (2018.01); C12M 1/34 (2006.01); C12N 15/09 (2006.01); C12P 19/34 (2006.01); C12Q 1/04 (2006.01); C12Q 1/6886 (2018.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01); G01N 37/00 (2006.01)

CPC C12Q 1/6886 (2013.01) [C12M 1/34 (2013.01); C12N 15/09 (2013.01); C12Q 1/04 (2013.01); G01N 33/53 (2013.01); G01N 33/574 (2013.01); G01N 37/00 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)]

4 Claims

1. A method for detecting liver cancer in a human subject, comprising:

measuring an expression level of hsa-miR-5787 in a blood, serum or plasma sample from the subject;

comparing the measured expression level of hsa-miR-5787 to a control expression level of hsa-miR-5787 for a healthy subject;

detecting an increased level of hsa-miR-5787 in the sample from the subject as compared to the control expression level from the sample from the healthy subject, wherein the increased level of hsa-miR-5787 indicates that the subject has liver cancer; and

wherein the method further comprises treating the subject for the liver cancer or performing a diagnostic procedure on the subject with the liver cancer;

wherein the treating comprises: surgical resection and/or liver transplantation; local therapy which involves injecting a drug through centesis or performing cauterization to kill cancer; or hepatic arterial embolization; optionally in combination with a drug therapy or radiotherapy, and

wherein the diagnostic procedure comprises a palpation or imaging test.